International Journal of Digital Health Volume 1 (2021), Article ID 1:IJDH-107, 8 pages
Original Article
Sustained Improvement of HbA1C in a Non-Randomized Trial Through Use of AI Virtual Health Assistant and Consumer Friendly Glucose Measurement for People with Diabetes

Tim Balder1 and Lonny Stormo2*

1Primary care physician with HealthPartners, Inc, United States
2CEO with Pops Diabetes Care, Inc, United States
Lonny Stormo, CEO with Pops Diabetes Care, Inc, United States, Cell: +1 763-639-3508; E-mail:
07 December 2021; 29 December 2021; 31 December 2021
Balder T, Stormo L (2021) Sustained Improvement of HbA1C in a Non- Randomized Trial Through Use of AI Virtual Health Assistant and Consumer Friendly Glucose Measurement for People with Diabetes. Int J Digt Hlthc 1: 107. doi:


Background: Management of diabetes has always depended upon sustained self-management by the person with diabetes. Data shows that people do a poor job of self-management. Some new approaches are beginning to implement artificial intelligence assistants to aid people with diabetes in their self-management. One such approach is the Pops digital self-care platform, which implements a digital assistant and integrated glucose meter. The aim of this study is to determine whether diabetes self-management can achieve a sustained improved HbA1c outcome with the use of the subject self-care platform.
Methods: The platform has been commercialized for more than 24 months. A prospective clinical registry has been established and currently includes 50 commercial users of the platform. Demographics include people with Pre-, Type I, and Type II diabetes, with 56% male, 44% female, and ages ranging from 19 to 77 years old. HbA1C reduction is the primary outcome, and it is examined using multiple population views.
Results: All total and sub-population data analyses show a significant reduction in HbA1C sustained for up to 24 months with the use of the platform. Across the total registry population, there is a significant decrease in HbA1C of 0.8 points [p= 0.001] in the first six months of use and a sustained improvement of HbA1c improvement of 1.3 points [p= 0.001] at 24 months of continuous use of the platform. Noteworthy is the sub-population of those with HbA1c greater than 7.0 at baseline, who demonstrated a 2.1 point [p= 0.001] improvement in HbA1c at six months with that improvement increasing to 3.3 points [p= 0.001] at a sustained 24 months of use.
Conclusions: These results demonstrate that the studied platform for self-management can improve sustained diabetes management results. Future analysis and publications of the registry data will include additional participants, improved compliance toward ADA guidelines, and glucose time in range.